David Robbins is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 N. Flamingo
Suite #101a
Pembroke Pines, FL 33028
Telephone
954-441-9550Provider last certified this registry record 30 Aug 2021.
Clinical trials
- The I-KAN Study: Internet Insulin Education for Kansans
Sponsor: David Robbins, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20255 payments
- Blue Earth Diagnostics LimitedProgram year20242 payments
- PFIZER INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.2%Cholinesterase Inhibitor22.6%Donepezil Hcl96%Rivastigmine5%Part D<11 patientsGabapentinoids22.2%Gabapentin89%Pregabalin11%Part D≥109 patients+ 16 more classes in this area
Cardiovascular
1.5%Beta blocker1.5%Propranolol Hcl Er100%Part D<11 patientsMusculoskeletal
1.3%Neuromuscular Blocker1.3%Botox100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2009–2021 per NIH RePORTER. The latest:
- Targeting Wnt-dependent colorectal cancer
University of Miami School of Medicine
FY2021$166,963R01CA219189 - Targeting Wnt-dependent colorectal cancer
University of Miami School of Medicine
FY2020$405,303R01CA219189 - Novel regulators of Gli-driven medulloblastoma
University of Miami School of Medicine
FY2020$340,037R01NS110591
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”